SCHEMBL5385950

SCHEMBL5385950

Clc1ccccc1-c1cc2nccc(Cl)n2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.46
THRB P10828 2/20 0.46
NPC1 O15118 3/20 0.42
RAB9A P51151 2/20 0.42
LMNA P02545 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
DPP4 P27487 1/20 0.41
DPP8 Q6V1X1 1/20 0.41
DPP9 Q86TI2 1/20 0.41
EGLN2 Q96KS0 1/20 0.38
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
KDM4E B2RXH2 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
CYP19A1 P11511 1/20 0.37
IDO1 P14902 1/20 0.37
ALDH1A1 P00352 1/20 0.36
DCTPP1 Q9H773 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15191566 0.85 HTR2C (0.45) MAPTTHRBNPC1RAB9ALMNA
SCHEMBL16116481 0.85 MAPT (0.50) MAPTTHRBNPC1RAB9ALMNA
SCHEMBL5564110 0.82 NPC1 (0.60) MAPTTHRBNPC1RAB9ALMNA
SCHEMBL5381153 0.76 DPP4 (0.53) MAPTNPC1RAB9ADPP4DPP8
SCHEMBL4837313 0.74 KDM5B (0.44) MAPTTHRBDPP4DPP8DPP9
SCHEMBL5564416 0.70 MAPT (0.61) MAPTNPC1RAB9AL3MBTL1DPP4
SCHEMBL15191900 0.69 NPC1 (0.36) MAPTTHRBNPC1RAB9ALMNA
SCHEMBL12789269 0.69 NPC1 (0.56) MAPTTHRBNPC1RAB9AL3MBTL1
SCHEMBL12303171 0.68 CCR1 (0.57) MAPTNPC1RAB9ALMNAHSP90AA1
SCHEMBL1396125 0.68 FYN (0.36) MAPTTHRBNPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US disclosed
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US disclosed
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US disclosed
EP-1594872-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF Pfizer Products Inc. (US) 2005-11-16 EP disclosed
WO-2005103052-A1 PYRAZOLO [1,5-A] PYRIMIDIN-7-ONE COMPOUNDS AND USES THEREOF PFIZER PRODUCTS INC. (US) 2005-11-03 WO disclosed
WO-2004069838-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PFIZER PRODUCTS INC. (US) 2004-08-19 WO disclosed
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof CNR1, CNR2, GPR18 MAPT 2827/4885THRB 383/4885NPC1 650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.